Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
793
datasets available to search
ShareScore release 0.9.0
Dataset results
793 results for “Startes”
Start from Scratch: Precisely Identify Massive Active Enhancers by Sequencing
GEO Series GSE129453. Homo sapiens. 1 samples. Type: Other.
A genome-wide map of transcription start sites specific for acute promyelocytic leukemia reveals deregulation of full-length transcripts
GEO Series GSE46561. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.
Gene expression in green millet (Setaria viridis): developmentally regulated genes, transcription start sites, and stimulating introns
GEO Series GSE89855. Setaria viridis. 13 samples. Type: Expression profiling by high throughput sequencing.
Parallel transcriptional programs driving early-starting inheritable lineage bias of myeloid, lymphoid and dendritic cells are initiated by distinct dosage of PU.1 and IRF8 in HSCs
GEO Series GSE89020. Homo sapiens. 26 samples. Type: Expression profiling by high throughput sequencing.
DNA methylation at transcription start sites blocks TBP binding and transcription onset by RNApolII
GEO Series GSE60658. Mus musculus. 5 samples. Type: Methylation profiling by genome tiling array; Genome binding/occupancy profiling by high throughput sequencing; Methylation profiling by high throughput sequencing.
Global identification of Hfq-bound RNA and transcriptional start site mapping in Serratia marcescens.
GEO Series GSE78185. Serratia marcescens. 4 samples. Type: Expression profiling by high throughput sequencing.
miRNA expression data from adult mouse Prefrontal Cortex following high fat diet exposure (8 weeks, starting on PND28)
GEO Series GSE105794. Mus musculus; synthetic construct. 12 samples. Type: Expression profiling by array.
Global identification of transcription start sites in the genome of Apis mellifera by using 5’ LongSAGE
GEO Series GSE19555. Apis mellifera. 1 samples. Type: Expression profiling by SAGE.
Students starting their university studies: focus group interview
<p>The aim of the focus group discussions is to find out what challenges students face when starting at university and how the pandemic has affected these challenges. The specific research questions are as follows: 1) What challenges and difficulties do university students in the three countries face when starting their university studies? 2) What support do first-year students need in order to effectively start and continue their studies at university and become a successful part of the academic community? 3) What additional challenges did first-year students face during the COVID-19 pandemic?</p>
Raw data for "Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration. Eur J Clin Pharmacol. 2023;79:1173-1184." and "Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways;Drugs R D. 2023 Sep 13. doi: 10.1007/s40268-023-00438-2."
<p><strong>Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways:</strong></p> <p><strong>Background and objective: </strong>N-terminal pro-B-type natriuretic peptide (NT-proBNP) and soluble interleukin 1 receptor-like 1 ST2 (sST2) are biomarkers used to grade heart failure with reduced ejection fraction (HFrEF) severity. Both are potential targets of HFrEF treatment, but the first is associated with the patient's hemodynamic status, while the second is more indicative of the inflammatory status and of myocardial fibrosis. The aim of this study was to assess the kinetics of these biomarkers after treatment with sacubitril/valsartan in HFrEF.</p> <p><strong>Methods: </strong>We analyzed blood samples of patients with HFrEF at baseline (before sacubitril/valsartan treatment), after 1, 2, and 3 months (respectively, after a month taking the 24/26 - 49/51 - 97/103 mg twice daily, or b.i.d., doses), and 6 months after the maximum-tolerated dose was reached (end study).</p> <p><strong>Results: </strong>We obtained samples from 72 patients with HFrEF (age 64.0 ± 10.5 years, 83% males). NT-proBNP and sST2 values progressively and significantly reduced to 37% and 16%, respectively, with a greater reduction for NT-proBNP (p < 0.001). Specifically, NT-proBNP reduced from 1144 [593-2586] pg/mL to 743 [358-1524] pg/mL and sST2 from 27.3 [20.5-35.0] ng/mL to 23.1 [15.9-30.7] ng/mL, p for trend < 0.001 in both cases. The reduction of the two biomarkers over time occurred with statistically significant different kinetics: deferred for sST2 and faster for NT-proBNP. No significant changes in renal function and potassium levels were recorded.</p> <p><strong>Conclusion: </strong>These findings suggest that, in patients with HF, sacubitril/valsartan effects on the cardiovascular system share a double pathway: a first, hemodynamic, faster pathway and a second, non-hemodynamic anti-fibrotic, delayed one. Both likely contribute to the sacubitril/valsartan benefits in HFrEF.</p> <p> </p> <p><strong>Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration</strong></p> <p><strong>Purpose: </strong>Sacubitril/valsartan is a mainstay of the treatment of heart failure with reduced ejection fraction (HFrEF); however, its effects on exercise performance yielded conflicting results. Aim of our study was to evaluate the impact of sacubitril/valsartan on exercise parameters and echocardiographic and biomarker changes at different drug doses.</p> <p><strong>Methods: </strong>We prospectively enrolled consecutive HFrEF outpatients eligible to start sacubitril/valsartan. Patients underwent clinical assessment, cardiopulmonary exercise test (CPET), blood sampling, echocardiography, and completed the Kansas City Cardiomyopathy Questionnaire (KCCQ-12). Sacubitril/valsartan was introduced at 24/26 mg b.i.d. dose and progressively uptitrated in a standard monthly-based fashion to 97/103 mg b.i.d. or maximum tolerated dose. Study procedures were repeated at each titration visit and 6 months after reaching the maximum tolerated dose.</p> <p><strong>Results: </strong>Ninety-six patients completed the study, 73 (75%) reached maximum sacubitril/valsartan dose. We observed a significant improvement in functional capacity across all study steps: oxygen intake increased, at peak exercise (from 15.6 ± 4.5 to 16.5 ± 4.9 mL/min/kg; p trend = 0.001), while minute ventilation/carbon dioxide production relationship reduced in patients with an abnormal value at baseline. Sacubitril/valsartan induced positive left ventricle reverse remodeling (EF from 31 ± 5 to 37 ± 8%; p trend < 0.001), while NT-proBNP reduced from 1179 [610-2757] to 780 [372-1344] pg/ml (p trend < 0.0001). NYHA functional class and the subjective perception of limitation in daily life at KCCQ-12 significantly improved. The Metabolic Exercise Cardiac Kidney Index (MECKI) score progressively improved from 4.35 [2.42-7.71] to 2.35% [1.24-4.96], p = 0.003.</p> <p><strong>Conclusions: </strong>A holistic and progressive HF improvement was observed with sacubitril/valsartan in parallel with quality of life. Likewise, a prognostic enhancement was observed.</p>
Effect of receipt of male ejaculate sex peptide on micro RNA expression in female Drosophila melanogaster, 3 hours after the start of mating, in HeadThorax (HT) and Abdomen (Abd) tissues.
GEO Series GSE31250. Drosophila melanogaster. 8 samples. Type: Non-coding RNA profiling by high throughput sequencing.
BRD4 loading at the transcription start site mediates pause-release and underlies the disproportionate transcriptional response to BET bromodomain inhibition
GEO Series GSE70450. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing; Other.
parameter and coordinate files to start an MD simulation of Haloferax volcanii ADH2
<p>parameter and coordinate files to start an MD simulation of Haloferax volcanii ADH2 in Amber</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.